Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy PI, New York, NY, USA.
Department of Medicine, University of Buffalo, New York, USA.
BMC Gastroenterol. 2024 Mar 25;24(1):119. doi: 10.1186/s12876-024-03205-y.
Acute pancreatitis poses a significant health risk due to the potential for pancreatic necrosis and multi-organ failure. Fluid resuscitation has demonstrated positive effects; however, consensus on the ideal intravenous fluid type and infusion rate for optimal patient outcomes remains elusive.
A comprehensive literature search was conducted using PubMed, Embase, the Cochrane Library, Scopus, and Google Scholar for studies published between 2005 and January 2023. Reference lists of potential studies were manually searched to identify additional relevant articles. Randomized controlled trials and retrospective studies comparing high (≥ 20 ml/kg/h), moderate (≥ 10 to < 20 ml/kg/h), and low (5 to < 10 ml/kg/h) fluid therapy in acute pancreatitis were considered.
Twelve studies met our inclusion criteria. Results indicated improved clinical outcomes with low versus moderate fluid therapy (OR = 0.73; 95% CI [0.13, 4.03]; p = 0.71) but higher mortality rates with low compared to moderate (OR = 0.80; 95% CI [0.37, 1.70]; p = 0.55), moderate compared to high (OR = 0.58; 95% CI [0.41, 0.81], p = 0.001), and low compared to high fluids (OR = 0.42; 95% CI [0.16, 1.10]; P = 0.08). Systematic complications improved with moderate versus low fluid therapy (OR = 1.22; 95% CI [0.84, 1.78]; p = 0.29), but no difference was found between moderate and high fluid therapy (OR = 0.59; 95% CI [0.41, 0.86]; p = 0.006).
This meta-analysis revealed differences in the clinical outcomes of patients with AP receiving low, moderate, and high fluid resuscitation. Low fluid infusion demonstrated better clinical outcomes but higher mortality, systemic complications, and SIRS persistence than moderate or high fluid therapy. Early fluid administration yielded better results than rapid fluid resuscitation.
急性胰腺炎会导致胰腺坏死和多器官衰竭,从而对健康造成重大威胁。液体复苏已被证明具有积极作用;然而,对于最佳患者结局所需的理想静脉输液类型和输注率,仍未达成共识。
使用 PubMed、Embase、Cochrane 图书馆、Scopus 和 Google Scholar 对 2005 年至 2023 年 1 月期间发表的研究进行了全面的文献检索。手动检索潜在研究的参考文献列表以确定其他相关文章。纳入了比较急性胰腺炎中高(≥20ml/kg/h)、中(≥10 至 <20ml/kg/h)和低(5 至 <10ml/kg/h)液体疗法的随机对照试验和回顾性研究。
符合纳入标准的研究有 12 项。结果表明,与中液疗法相比,低液疗法可改善临床结局(OR=0.73;95%CI [0.13, 4.03];p=0.71),但低液疗法的死亡率高于中液疗法(OR=0.80;95%CI [0.37, 1.70];p=0.55),中液疗法的死亡率高于高液疗法(OR=0.58;95%CI [0.41, 0.81],p=0.001),低液疗法的死亡率高于高液疗法(OR=0.42;95%CI [0.16, 1.10];p=0.08)。与低液疗法相比,中液疗法可改善系统性并发症(OR=1.22;95%CI [0.84, 1.78];p=0.29),但中液疗法与高液疗法之间无差异(OR=0.59;95%CI [0.41, 0.86];p=0.006)。
本荟萃分析揭示了接受低、中、高液体复苏的急性胰腺炎患者的临床结局存在差异。低液输注显示出更好的临床结局,但死亡率、系统性并发症和 SIRS 持续存在的风险高于中或高液疗法。早期液体给药比快速液体复苏产生更好的结果。